Writing and thinking from the Workomics team

For brands, communicating clinical trial results is usually paramount—the clinical efficacy data, balanced by the side effects observed, is the foundation of the product’s value proposition for patients. But clinical trial data is typically complex, and can be difficult for patients to understand.

Important Safety Information appears throughout branded patient marketing materials. It captures key information that patients with advanced and complex diseases want to know, and supports informed consent for important treatment decisions. Countless hours of co-creation time with patients, caregivers, HCPs, and subject matter experts has helped us think differently about how we can communicate ISI to patients.

Patients with rare and complex diseases need brand marketing materials that offer concrete support. That’s why our approach is built on clear and effective communication, holistically integrating UX, visuals, clinical trial data, and important safety information.

Back to Ideas Some time ago, we came across an insightful article in the MIT Technology Review discussing the rollout of Sepsis Watch, a...

The experience of using and designing a form – an integral step to providing care that shapes the overall patient experience